Effects of levosimendan in experimental acute coxsackievirus myocarditis

European Journal of Clinical Investigation

Volumn 39, Issue 10, 2009, Pages 876-882

  Latva Hirvela J ^a   Kyto V ^a,b,c   Saraste, A ^b   Vuorinen, T ^a   Levijoki, J ^d   Saukko, P ^a  

^a UNIVERSITY OF TURKU   (Finland)

^b TURKU UNIVERSITY HOSPITAL   (Finland)

^c SATAKUNTA CENTRAL HOSPITAL   (Finland)

^d ORION CORPORATION   (Finland)

Author keywords

Apoptosis; Enterovirus; Heart failure; Inotropic; Myocarditis; Treatment

Indexed keywords

LEVOSIMENDAN;

ACUTE HEART FAILURE; ADOLESCENT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CONTROLLED STUDY; COXSACKIE VIRUS B3; HEART LEFT VENTRICLE FUNCTION; HEART PERFORMANCE; HISTOPATHOLOGY; INFLAMMATION; MORTALITY; MOUSE; MUSCLE CONTRACTILITY; NICK END LABELING; NONHUMAN; PRIORITY JOURNAL; SURVIVAL; TITRIMETRY; TRANSTHORACIC ECHOCARDIOGRAPHY; VIRUS MYOCARDITIS; VIRUS REPLICATION;

ANIMALS; CARDIOTONIC AGENTS; COXSACKIEVIRUS INFECTIONS; HEART FAILURE; HYDRAZONES; MALE; MICE; MICE, INBRED BALB C; MYOCARDITIS; MYOCARDIUM; MYOCYTES, CARDIAC; PYRIDAZINES; VENTRICULAR FUNCTION, LEFT;

EID: 70349232752     PISSN: 00142972     EISSN: 13652362     Source Type: Journal    
DOI: 10.1111/j.1365-2362.2009.02202.x     Document Type: Article

References (32)

1. Lieberman EB, Hutchins GM, Herskowitz A, Rose NR, Baughman KL. Clinicopathological description of myocarditis. J Am Coll Cardiol 1991 18 : 1617 1626.
2. McCarthy RE III., Boehmer JP, Hruban RH, Hutchins GM, Kasper EK, Hare JM et al. Long-term outcome of fulminant myocarditis as compared with acute (nonfulminant) myocarditis. N Engl J Med 2000 342 : 690 695.
3. Wencker D, Chandra M, Nguyen K, Miao W, Garantziotis S, Factor SM et al. A mechanistic role for cardiac myocyte apoptosis in heart failure. J Clin Invest 2003 111 : 1497 1504.
4. Kytö V, Saraste A, Saukko P, Henn V, Pulkki K, Vuorinen T et al. Apoptotic cardiomyocyte death in fatal myocarditis. Am J Cardiol 2004 94 : 747 750.
5. Saraste A, Arola A, Vuorinen T, Kytö V, Kallajoki M, Pulkki K et al. Cardiomyocyte apoptosis in experimental coxsackievirus B3. Cardiovasc Pathol 2003 12 : 255 262.
6. De Luca L, Colucci WS, Nieminen MS, Massie BM, Gheorghiade M. Evidence-based use of levosimendan in different clinical settings. Eur Heart J 2006 27 : 1908 1920.
7. Haikala H, Kaivola J, Nissinen E, Wall P, Levijoki J, Linden IB. Cardiac troponin C as a target protein for a novel calcium sensitizing drug, levosimendan. J Mol Cell Cardiol 1995 27 : 1859 1866.
8. Haikala H, Nissinen E, Etemadzadeh E, Levijoki J, Linden IB. Troponin C-mediated calcium sensitization induced by levosimendan does not impair relaxation. J Cardiovasc Pharmacol 1995 25 : 794 801.
9. Kaheinen P, Pollosello P, Levijoki J, Haikala H. Levosimendan increases diastolic coronary flow in isolated guinea-pig heart by opening ATP-sensitive potassium channels. J Cardiovasc Pharmacol 2001 37 : 367 374.
10. Yokoshiki H, Katsube Y, Sunagawa M, Sperelakis N. The novel calcium sensitizer levosimendan activates the ATP-sensitive K channel in rat ventricular cells. J Pharmacol Exp Ther 1997 283 : 375 383.
11. Ukkonen H, Saraste M, Akkila J, Knuuti MJ, Lehikoinen P, Någren K et al. Myocardial efficience during calcium sensitization with levosimendan: a noninvasive study with positron emission tomography and echocardiography in healthy volunteers. Clin Pharmacol Ther 1997 61 : 596 607.
12. Slawsky MT, Colucci WS, Gottlieb SS, Greenberg BH, Haeusslein E, Hare J et al. Acute hemodynamic and clinical effects of levosimendan in patients with severe heart failure. Study Investigators. Circulation 2000 102 : 2222 2227.
13. Follath F, Cleland JG, Just H, Papp JG, Scholz H, Peuhkurinen K et al. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial. Lancet 2002 360 : 196 202.
14. Moiseyev VS, Poder P, Andrejevs N, Ruda MY, Golikov AP, Lazebnik LB et al. Safety and efficacy of a novel calcium sensitizer, levosimendan, in patients with left ventricular failure due to an acute myocardial infarction. A randomized, placebo-controlled, double-blind study (RUSSLAN). Eur Heart J 2002 23 : 1422 1432.
15. Maytin S, Colucci WS. Cardioprotection: a new paradigm in the management of acute heart failure syndromes. Am J Cardiol 2005 96 : 26G 31G.
16. Louhelainen M, Vahtola E, Kaheinen P, Leskinen H, Merasto S, Kytö V et al. Effects of levosimendan on cardiac remodelling and cardiomyocyte apoptosis in hypertensive Dahl/Rapp rats. Br J Pharmacol 2007 150 : 851 861.
17. Antila S, Sundberg S, Lehtonen LA. Clinical pharmacology of levosimendan. Clin Pharmacokinet 2007 46 : 535 552.
18. Latva-Hirvelä J, Kytö V, Saraste A, Eriksson S, Vuorinen T, Pettersson K et al. Development of troponin autoantibodies in experimental coxsackievirus B3 myocarditis. Eur J Clin Invest 2009 39 : 457 462.
19. Tanaka N, Dalton N, Mao L, Rockman HA, Peterson KL, Gottshall KR et al. Transthoracic echocardiography in models of cardiac disease in the mouse. Circulation 1996 94 : 1109 1117.
20. Mason JW, O'Connell JB, Herskowitz A, Rose NR, McManus BM, Billingham ME et al. A clinical trial of immunosuppressive therapy for myocarditis. The Myocarditis Treatment Trial Investigators. N Engl J Med 1995 333 : 269 275.
21. Mebezaa A, Nieminen MS, Packer M, Cohen-Solal A, Kleber FX, Pocock SJ et al. Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE Randomized Trial. JAMA 2007 297 : 1883 1891.
22. Kytö V, Lapatto R, Lakkisto P, Saraste A, Voipio-Pulkki LM, Vuorinen T et al. Glutathione depletion and cardiomyocyte apoptosis in viral myocarditis. Eur J Clin Invest 2004 34 : 167 175.
23. Boost KA, Hoegl S, Dolfen A, Czerwonka H, Scheiermann P, Zwissler B et al. Inhaled levosimendan reduces mortality and release of proinflammarory mediators in a rat model of experimental ventilator-induced lung injury. Crit Care Med 2008 36 : 1979 1981.
24. Parissis JT, Adamopoulos S, Antoniades C, Kostakis G, Rigas A, Kyrzopoulos S et al. Effects of levosimendan on circulating pro-inflammatory cytokines and soluble apoptosis mediators in patients with decompensated advanced heart failure. Am J Cardiol 2004 93 : 1309 1312. (Pubitemid 38595693)
25. Adamopoulus S, Parissis JT, Iliodromitis EK, Paraskevaidis I, Tsiapras D, Farmakis D et al. Effects of levosimendan versus doputamine on inflammatory and apoptotic pathways in acutely decompensated chronic heart failure. Am J Cardiol 2006 98 : 102 106.
26. Giordano FJ. Oxygen, oxidative stress, hypoxia, and heart failure. J Clin Invest 2005 115 : 500 508.
27. Kopustinskiene DM, Pollosello P, Saris NE. Levosimendan is a mitochondrial K(ATP) channel opener. Eur J Pharmacol 2001 428 : 311 314.
28. Akao M, Ohler A, O'Rourke B, Marban E. Mitochondrial ATPsensitive potassium channels inhibit apoptosis induced by oxidative stress in cardiac cells. Circ Res 2001 88 : 1267 1275.
29. Parissis JT, Andreadou I, Markantonis SL, Bistola V, Louka A, Pyriochou A et al. Effects of levosimendan on circulating markers of oxidative and nitrosative stress in patients with advanced heart failure. Atherosclerosis 2007 195 : e210 5.
30. Toyozaki T, Hiroe M, Saito T, Iijima Y, Takano H, Hiroshima K et al. Levels of soluble Fas in patients with myocarditis, heart failure of unknown origin, and in healthy volunteers. Am J Cardiol 1998 81 : 798 800.
31. Satoh M, Tamura G, Segawa I, Tashiro A, Hiramori K, Satodate R. Expression of cytokine genes and presence of enteroviral genomic RNA in endomyocardial biopsy tissues of myocarditis and dilated cardiomyopathy. Virchows Arch 1996 427 : 503 509.
32. Ding B, Abe J, Wei H, Huang Q, Walsh RA, Molina CA et al. Functional role of phosphodiesterase 3 in cardiomyocyte apoptosis: implication in heart failure. Circulation 2005 111 : 2469 2476.